SNYNF (Sanofi) Pre-Tax Income : $6,127 Mil (TTM As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sanofi Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Sanofi's pretax income for the six months ended in Jun. 2024 was $2,948 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2024 was $6,127 Mil. Sanofi's pretax margin was 12.17%.

During the past 13 years, Sanofi's highest Pretax Margin was 36.87%. The lowest was 7.31%. And the median was 15.88%.

Sanofi Pre-Tax Income Historical Data

The historical data trend for Sanofi's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Pre-Tax Income Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

3,057.78

16,761.56

8,811.30

11,040.25

7,800.44

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Pre-Tax Income	Get a 7-Day Free Trial															3,883.72	7,148.31	4,591.55	3,178.84	2,948.33

Competitive Comparison of Sanofi's Pre-Tax Income

For the Drug Manufacturers - General subindustry, Sanofi's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Pre-Tax Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Sanofi's Pre-Tax Income falls into.

Sanofi Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Sanofi's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	11332.606	+	-2835.333	+	-718.648	+	595.42	+	-573.609
	=	7,800

Sanofi's Pretax Income for the quarter that ended in Jun. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	4856.835	+	-1579.117	+	-417.653	+	261.572	+	-173.305
	=	2,948

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $6,127 Mil.

Sanofi (OTCPK:SNYNF) Pre-Tax Income Explanation

Sanofi's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	2948.332	/	24217.438
	=	12.17%

During the past 13 years, Sanofi's highest Pretax Margin was 36.87%. The lowest was 7.31%. And the median was 15.88%.

Sanofi Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Sanofi's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (OTCPK:SNYNF) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

SNY:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.